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Purpose: To develop a floating multiparticulate unit system for metoprolol tartarate, using a porous 
carrier, with an outcome for delayed gastric emptying. 
Methods: Dried microparticles of metoprolol tartarate were prepared by solvent evaporation using 
Eudragit
®
 RS-PO, polypropylene foam powder, and dichloromethane as release-rate modifying polymer, 
floating aid and solvent respectively. The surface topography of the particles was assessed by SEM 
while the physical state of the drug within the developed system was characterised by DSC and XRD. 
Drug release was investigated by in vitro dissolution test. Tc99m sulfur colloid radio-labelled 
microparticle formulation was administered to fasting rabbits and their transit behavior was monitored 
using gamma scintigraphy. The anterior and posterior images recorded were computed to determine the 
geometric mean counts, enabling quantitative estimation of gastric emptying rate. 
Results: Dried free-flowing, white coloured microparticles were obtained. They were highly porous and 
also irregular in shape. The drug in the microparticles was partly amorphous, showing a decrease in 
crystallinity. In vitro drug release from the particles followed a biphasic pattern with zero-order kinetics. 
The microparticulate system exhibited good floating ability with t1/2 of 300 min over the duration of the in 
vivo study (6 h). 
Conclusion: The developed microparticles showed suitable release properties, were free-flowing and 
exhibited good floating ability in rabbit stomach. Therefore, the formulation is capable of being further 
processed into tablet and/or capsule dosage forms for oral administration as a gastro-retentive 
controlled delivery system. 
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INTRODUCTION 
 
"Less dense porous materials (meso, micro, 
nano) have been evinced as controlled drug 
delivery matrices" due to a stable uniform 
porous structure, tunable pore size with 
narrow distribution and higher surface area, 
enabling adsorption of drugs and their 
release in a reproducible and predictable 
fashion [1]. Successful per-oral intragastric 
floating dosage forms a lower bulk density 
than gastric fluids and remain buoyant in 
stomach contents without affecting gastric 
emptying rate [2]. Multi-particulate unit 
systems are preferred to single-unit forms 
because of their consistent gastric emptying 
and predictable absorption - release profile, 
thus reducing the risk of dose-dumping and 
improved patient compliance [3].  
 
For desired therapeutic efficacy, constant 
plasma concentration of a cardiovascular 
drug has to be maintained.  Metoprolol 
tartarate, a β1 selective adrenergic blocker 
whose absorption rate is directly proportional 
to dose availability4, has a half-life of 3 to 4 h, 
and thus requiring multiple doses to attain 
constant plasma concentration. 
Polypropylene foam powder, Accurel® MP 
10005, acting like sponges, exhibits an open 
cell structure with interconnected pores. 
United States Food and Drug Administration 
(FDA) has approved polymethacrylates such 
as Eudragit RSPO as an additive in drug 
formulation6.  
 
The objective was to develop a peroral 
intragastric floating dosage form with 




Polypropylene foam powder (Accurel® MP 
1000, Membrana GmbH, Obermburg, 
Germany), metoprolol tartarate (Amanath 
Pharmaceuticals, India), Eudragit RSPO 
(Rohm Pharma, GmbH, Darmstadt, 
Germany), ethanol (Hong Yang International 
Co, China) dichloromethane (SD Fine 
Chemicals, India), Tween 20 (Vin Biotech, 
India) were among the materials used. Cold 
kits were supplied by the Board of Radiation 
and Isotope Technology (BRIT), Barc, India. 
Hydrochloric acid and sodium hydroxide 
pellets were of analytical grade.  
Polypropylene foam powder was sieved to a 
particle size range of 250 -315 um size prior 
to use. 
 
Preparation of microparticles  
 
Microparticles were prepared by first 
dissolving Eudragit RSPO and metoprolol 
tartarate in an organic solvent, 
dichloromethane, as previously described [7]. 
The polypropylene foam powder was 
dispersed in the organic mixture and the 
resulting suspension poured in to a Teflon 
dish. The polypropylene foam particles acted 
like sponges with the ability to absorb the 
organic solution. After solvent evaporation at 
room temperature under ambient pressure, 
free-flowing microparticles were obtained. 
Four different formulations were prepared 
with the drug and carrier kept constant while 
varying the polymer content (see Table 1). 
The yield of microcapsules was assessed as 
in Eq 1. 
 
100  x  Wdp/  Wm(%) =Yield ……… (1) 
 
where Wm and Wdp represent total weight of 
floating microparticles and drug + polymer, 
respectively. 
 
Table 1: Yield and encapsulation efficiency of 
microparticle formulation containing 100 and 150 
mg of drug and carrier, respectively (n = 3). 
 
Formulation 








A 150 97.0 92.0 + 0.1 
B 250 97.5 95.0 + 0.2 
C 400 97.0 98.0 + 0.1 




A quantity (50 mg) of microparticles was 
soaked in 50 ml of ethanol followed by 
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agitation with a magnetic stirrer for 12 h and 
then filtered through a 0.45 um filter paper. 
Drug concentration in the ethanol phase was 
determined spectrophotometrically (UV-1601, 
Shimadzu) at 276 nm. Encapsulation 
efficiency was computed from Eq 2. 
     
E = Da/Dt …………………………………  (2)  
 
where E, Da , Dt represent encapsulation 
efficiency, drug content (actual), 




The microparticles were placed in a stub and 
then coated for 120 s, with platinum at 20 
milli amperes and 8 Pa using a Jeol JFC - 
Autofine coater. The coated samples were 
then examined with a scanning electron 
microscope (JEOL, Japan, model JSM -6360)
  
In vitro drug release 
 
A quantity of floating microparticles, 
equivalent to 100 mg drug, was filled into a 
hard gelatin capsule (No. 0) and placed in a 
basket immersed in 900 ml of simulated 
gastric fluid (SGF) without pepsin maintained 
at 37 ± 1 °C and rotated at a speed of 75 rpm 
in a United States Pharmacopoeia (USP) 
XXIII basket type dissolution apparatus (TDT-
08L, Electrolab, India).  Five millilitre samples 
were withdrawn at intervals over a period of 8 
h, passed through a 0.45 µm filter and the 
filtrate analysed spectrophotometrically at 
274nm. Sink conditions were maintained 
during the test. Drug release rate kinetics 
was assessed by fitting the release data into 
dissolution kinetic study models Zero order, 
First order, Higuchi, Korsemeyer-Peppas  
and Hixon–Crowell. 
 
Differential scanning calorimetry (DSC) 
 
Netzsch DSC 204 scanning calorimeter 
equipped with a thermal analysis data system 
was used to record thermograms for 5-15 mg 
samples of the materials and formulations in 
the temperature range of 20 to 200 °C and at 
a heating rate of 10 K/min under a nitrogen 
atmosphere. The samples were sealed in 
aluminium crucibles, with the lid perforated, 
prior to the test. An empty aluminum crucible 
was used as the reference. 
 
X-ray powder diffraction (XRD) 
 
Wide angle x-ray scattering measurements 
were carried out on a high resolution powder 
diffractometer (Rich Seifert JSO Debye flex 
2002) with guinier geometry. X-ray diffraction 
patterns were recorded automatically at a 
scanning rate of 0.02 ° 29 per sec over the 
range of 10° - 70°, 20. The average particle 
(grain) size was calculated from Scherer 
formula, shown in Eq 3 [8] 
 
D = 0.9 λ/ β cos θ  …………………….  (3) 
 
where λ is the wavelength of copper Kα line 
(1.5406Å), θ is the diffraction angle,  β is 
the full width at half maximum of the peak, 







Radiolabelling of the microparticles was 
effected by direct labeling method [9], i.e., 
physical adsorption. Eudragit RSPO (250 mg) 
was dissolved in 3 ml of dichloromethane; 
100 mg of metoprolol tartarate was added to 
it and stirred until a clear solution was 
formed; 40 MBq of cold kit of 99™Tc - sulphur 
colloid solution was added and stirred 
vigorously for 15 min. The radioactive mixture 
was then adsorbed on to 150 mg 
polypropylene foam powder. Labeling 
efficiency was assessed by placing a drop of 
the aqueous dispersion on a pre-coated silica 
gel plate. After eluting the dried plate in 
normal saline in an ascending mode, the 
plate was examined for total radioactivity 
counts.  
 
Acquisition of images by gamma 
scintigraphy 
 
Three healthy New Zealand white rabbits with 
no past history of gastro-intestinal (Gl) 
disease were fasted for 12 h prior to the 
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commencement of the experiment. The study 
was approved by the Committee for the 
Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA) and the 
Institutional Animal Ethics Committee (IAEC) 
at Veterinary Nuclear Medicine Centre, 
Bombay Veterinary College, Mumbai. The 
procedure followed was as previously 
described [10]. Labelled metoprolol tartarate 
containing 8mg of the drug in 40 mg of 
microparticles with 40 MBq radioactivity (an 
average of 33.33MBq dose of labeled drug) 
were fed orally to each rabbit. Anterior 
posterior static images were acquired in 128 
x 128 matrix for 1 min at the following times: 
30, 60, 120, 180, 240, 300, 360 and 480 min 
post feeding using a gamma camera 
(Millenium MPS M/S GE ) fitted with low 
energy general purpose (LEGP) collimator at 
an energy set at 140 kev at 20 % window . 
The recorded images from an online 
computer system (Genie Workstation) were 
examined (with the aid of Entegra workstation 
software) for gastric retention of the fed 
material. Post-scan animals were permitted 
to move freely but were not allowed to take 
any food or water for the entire study period. 
The percentage of retained gastric activity of 
labeled drug was calculated from the anterior 
and posterior images recorded. PRGA versus 
time curve was plotted (see Fig 3). A linear fit 
curve with slope values of - 0.99, -0.24 and 
0.56 at 180, 300 and 360 minutes, 
respectively, was obtained with the aid of 
Excel program, and t½ was calculated 
manually from the curve for % retained. The 
acquired images were analysed as in Eq 4. 
 
 Geometric mean = A x P ……………….   (4) 
 
where A is the anterior image total count and 
P is the posterior image total count. Decay 
corrections of images were carried out and 
decay correction factor [11] for 99m Tc at 6 h, 
which was 0.500, was used to calculate 
percent retained gastric activity (PRGA) as in 
Eq 5. 
 100  x  Dt/  Dtg    PRGA =  …………  (5) 
 
where PRGA is the retained gastric activity 
(%), Dtg is the  decay corrected geometric 
mean at a given time, and Dt is the decay 






As shown in Table 1, encapsulation 
efficiencies were high in all cases (about 80 
%). The original polypropylene foam powder 











Fig 1: SEM images of population of formulated 
microparticles (left) and agglomeration of 
microparticles prepared at high polymer: drug ratio 
(400:100, right) indicates that the microparticles 
exhibited irregular shape with their pores (open 




DSC thermograms are shown in Fig 2. 
Endothermic peaks at 126.6, 163.6 and 58.6 
0C, corresponding to metoprolol tartarate, 
polypropylene foam powder, Eudragit RSPO, 
were observed. The physical mixture of these 
components showed their individual 
characteristic peaks which indicated there 
was no interaction between the components. 
Microparticles showed polypropylene peak at 
163.6° C while the film cast from an organic 





Diffractograms from XRD studies are shown 
in Fig 2. The mean crystal (grain) size of the 
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drug decreased from 1.0087 x 10-7 to 0.3338 
x 10-7 micrometers. 
 
 
Fig 2: DSC thermograms (left) and x-ray 
diffractograms (right) of microparticle formulation 




The drug release data are shown in Fig 3. 
The pattern was mostly biphasic with an 
initial rapid drug release phase (burst effect) 
followed by a second slower drug release 
phase for all the formulations. At higher 
polymer concentrations, burst effect was 
minimal. The controlled release property of 
the polymer was confirmed by comparing the  
 
 
Fig 3: Dissolution characteristics of micro-particles 
T80% of microparticles (840 min) to that of the 
commercial formulation, Lopressor® SR 
tablets (710 min). 
 
Gastric imaging studies 
 
Radiolabelling efficiency of the formulation 
was 65 %. There was good floating ability of 
the radiolabeled microparticles containing 
metoprolol tartarate in vivo over the period of 
study. The value of t½ was 300 min which 
was calculated using the linear trend line, as 
shown in Fig 4. 
 
Fig 4: Mean retained gastric activity (PRGA, %) of 
labelled metoprolol tartarate. Note: ♦ = mean 




Encapsulation efficiency was high due to the 
formulation technique employed, which 
entailed the use of only an organic phase. 
The non-use of aqueous phase accounted for 
the minimal drug loss. Excessive heating 
temperature and decreased viscosity of the 
aqueous polymeric solution would have 
decelerated the rate of film formation over the 
polypropylene foam powder (aqueous 
solvent). This why drug entrapment also 
increased as the polymer proportion in the 
microparticles increased. The aggregation of 
the microparticles is attributed to the 
presence of excess polymer which also 
occluded the inner pores of the particles. 
DSC thermograms suggest that the drug in 
the microparticle was partly dissolved in the 
polymer and that it was partially amorphous. 
This is buttressed by the fact that the 
polypropylene free film did not show any 
endotherm that indicates melting of the drug 
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which would have meant that the drug was 
crystalline.  
 
The XRD patterns also show that the drug in 
the microparticles is not crystalline or, at 
least, has decreased in crystallinity. The 
decrease in crystal size also suggests that 
the crystallinity of the drug fell thus favouring 
its slow release in the microparticle 
formulation [12]. At an enhanced polymer 
concentration, unlike at the lower polymer 
content, burst effect was not evident because 
the release medium could no longer gain 
access to the drug within the microparticles 
since the polymer completely covered the 
drug. All the formulations, except batch D 
which had the lowest polymer concentration, 
exhibited diffusion - controlled release since 
the release followed zero order kinetics.  
 
Good floating behavior was due to the low 
apparent density of the microparticles which 
in turn can be attributed to the porous nature 
of the polypropylene foam powder that 
created a highly porous internal and external 
structure within the microparticles. With the 
polymer partially covering the pores, air is 
trapped within the microparticles, thus 
causing them to be buoyant in aqueous 
medium. Since the entrapped air is released 
slowly from the microparticles, the latter 




A multiparticulate unit floating dosage form 
based on microporous polypropylene has 
been formulated. Drug release from the 
formulation was biphasic and showed zero-
order kinetics. Optimisation studies on the 
formulation have been planned which will 
facilitate further development into tablet 
and/or capsule dosage forms for oral gastro-
retentive delivery.  
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